Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis.

Details

Ressource 1Download: diagnostics-10-00002.pdf (1914.01 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_287C68962BA4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis.
Journal
Diagnostics
Author(s)
Meyer M., Nicod Lalonde M., Testart N., Jreige M., Kamani C., Boughdad S., Muoio B., Becce F., Schaefer N., Candrian C., Giovanella L., Prior J.O., Treglia G., Riegger M.
ISSN
2075-4418 (Print)
ISSN-L
2075-4418
Publication state
Published
Issued date
18/12/2019
Peer-reviewed
Oui
Volume
10
Number
1
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Tumor-induced or oncogenic osteomalacia (TIO) is a rare paraneoplastic syndrome in which osteomalacia is a consequence of fibroblast growth factor 23 (FGF23) secretion by a mesenchymal tumor. The localization of the culprit lesion in patients with TIO is often challenging. Several studies have evaluated the detection rate (DR) of these tumors using somatostatin receptor positron emission tomography (SSTR-PET/CT). We aimed to summarize literature findings on this topic providing pooled estimates of DR.
A comprehensive literature search by screening PubMed, Embase and Cochrane library electronic databases through August 2019 was performed. The pooled DR of culprit tumors using SSTR-PET/CT in patients with TIO was calculated using a random-effects statistical model.
Fourteen studies on the use of SSTR-PET/CT in detecting the culprit tumor in patients with TIO were included in the qualitative analysis. The pooled DR of SSTR-PET/CT on a per-patient-based analysis calculated using eleven studies (166 patients) was 87.6% (95% confidence interval (95% CI) 80.2-95.1%). Statistical heterogeneity among studies was detected (I-square = 63%), likely due to the use of different radiolabeled somatostatin analogues, as demonstrated by a subgroup analysis.
Despite limited literature data due to the rarity of the disease, SSTR-PET/CT demonstrated a very high DR of culprit tumors in patients with TIO and it could be used as first-line imaging method for this indication.
Keywords
PET, culprit tumor, detection rate, meta-analysis, osteomalacia, somatostatin, systematic review
Pubmed
Open Access
Yes
Create date
23/12/2019 12:28
Last modification date
15/01/2021 8:08
Usage data